Every practice that buys numbing cream eventually hits the same confusing wall. One supplier sells a 5% lidocaine cream by the case, ships it same day, and never asks who you are. Another asks for your NPI, your state license, and the name of the provider it will be dispensed under — and then makes something four times stronger. Both are legal. Both are legitimate. They are operating under different sections of the Federal Food, Drug, and Cosmetic Act, and that single fact explains nearly every difference you will notice.
The short version
Section 503A covers traditional pharmacy compounding: a state-licensed pharmacy prepares a medication for an identified patient or provider, against a valid order. Section 503B covers outsourcing facilities: registered with the FDA, operating under current good manufacturing practice, producing batches of a limited list of preparations that can be sold as stock to facilities and distributors.
A 503A pharmacy can make you almost anything a provider can justify — including a triple-anesthetic BLT compound at 20% benzocaine, 10% lidocaine, and 10% tetracaine. It cannot batch-produce that compound and ship pallets of it to a wholesaler. A 503B facility can do the pallets. It is working from its own batch list and its own validated formulas, which is a much shorter menu.
Why the strength you want usually comes from a 503A
Over-the-counter topical anesthetics are governed by an FDA monograph that caps what can be sold without a prescription — which is why the strongest thing on a retail shelf tends to be 4% or 5% lidocaine. Anything meaningfully stronger, or combining three anesthetics to get faster onset and longer duration in one application, sits outside that monograph. It has to be compounded for a provider or manufactured as an approved drug.
No one is going to run a new drug application for a numbing cream. So in practice, the strong stuff comes from compounding. That is the whole reason the 20/10/10 triple-anesthetic formula exists in the first place: three agents with different onset curves and different tissue affinities, layered to do in twenty minutes what a single 5% agent does poorly in forty. We break that pharmacology down on the science page, and compare it head to head on BLT vs OTC lidocaine and BLT vs EMLA.
What "compounded fresh per order" actually buys you
Tetracaine and benzocaine are not indefinitely stable in a topical base. A batch produced for warehouse distribution has to survive a shelf life that assumes months of storage and unknown temperature history. A preparation compounded the week you ordered it does not carry that burden, which is a real difference in how the product performs on skin rather than a marketing line.
The cost of that is speed. You do not get a 503A compound the way you get a case of gauze. There is credentialing on the front end, and compounding time on each order. Practices that plan a standing order never notice; practices that call on Friday for a Monday clinic do.
Why a 503A cannot sell through a distributor the way a 503B can
This is where most confusion about "wholesale numbing cream" comes from. Section 503A conditions the exemption from certain FDA requirements on the preparation being compounded for an identified patient or provider, based on a valid order — not produced for stock and sold into a distribution channel. The same section places limits on how much compounded preparation can be distributed interstate. State boards of pharmacy layer their own licensure rules on top.
So when a distributor asks to buy a compounded BLT in bulk, warehouse it, and resell it under their own PO, the honest answer is no — not from a 503A. That is a 503B arrangement. What a 503A can do is work with the distributor as a partner: they introduce the practice, the pharmacy credentials the provider and dispenses under their order, and the product ships directly to the clinic. We built our partner program around exactly that structure, and we say so on the page rather than burying it.
Questions worth asking any numbing cream supplier
- Which section are you operating under? A supplier who cannot answer this immediately is a supplier who has not thought about it.
- Is this compounded per order or pulled from stock? Both are valid answers. Only one of them explains a 20/10/10.
- Can I see the licensure and compounding documentation? A legitimate pharmacy has this ready for your credentialing file. Ours is here.
- Who verifies that I am a licensed provider? If nobody does, you are buying an OTC product, whatever the label implies about strength.
- What states can you ship to? For a 503A this is a real constraint, not a formality.
Neither lane is better — they solve different problems
It would be convenient for us to tell you 503A is superior. It is not that simple. If you need a standard-strength preparation in volume, on a predictable schedule, with a distributor relationship and a PO process, a 503B outsourcing facility is genuinely the right structure. If you need a strength and base that no stock product carries, prepared for your provider and your procedure mix, that is a 503A, and the credentialing is the price of admission.
What you should not accept is a supplier blurring the two: marketing compounding-strength claims while operating like a stock reseller, or promising distributor terms that the statute does not permit. That ambiguity is not a paperwork problem. It shows up as inconsistent product and an awkward conversation with your compliance officer.
Where MediCaine sits
We are a 503A. Every jar is compounded against a valid provider order in a state-licensed pharmacy under USP-795 standards, after we verify the ordering provider through the CMS NPI Registry and their state license. That is why we can make the 20/10/10, why we ask questions before your first order, and why our partner program pays on referred accounts rather than selling you stock to resell. More about the pharmacy here.
If you are choosing between suppliers and want a straight answer about which lane fits your practice — including when the honest answer is "not us" — call the pharmacy. That conversation takes about five minutes.